Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in Biochem Biophys Res Commun

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    June 2021
  1. ZHENG X, Guo R, Liu Q, Wakae K, et al
    Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus.
    Biochem Biophys Res Commun. 2021;567:1-8.
    PubMed     Abstract available


    May 2021
  2. PADHI AK, Tripathi T
    Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.
    Biochem Biophys Res Commun. 2021;555:147-153.
    PubMed     Abstract available


    April 2021
  3. OHYA K, Imamura M, Teraoka Y, Uchida T, et al
    Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.
    Biochem Biophys Res Commun. 2021;559:78-83.
    PubMed     Abstract available


    November 2020
  4. SHARMA R, Kk S, Holmstrom ED, Westerlund F, et al
    Real-time compaction of nanoconfined DNA by an intrinsically disordered macromolecular counterion.
    Biochem Biophys Res Commun. 2020;533:175-180.
    PubMed     Abstract available


    August 2020
  5. KANDANGWA M, Liu Q
    HCV-2a NS5A downregulates viral translation predominantly through domain I.
    Biochem Biophys Res Commun. 2020;529:77-84.
    PubMed     Abstract available


    October 2019
  6. KANDANGWA M, Liu Q
    HCV NS5A hyperphosphorylation is involved in viral translation modulation.
    Biochem Biophys Res Commun. 2019 Oct 1. pii: S0006-291X(19)31841.
    PubMed     Abstract available


    May 2019
  7. SHIMIZU Y, Yoneda K, Shirasago Y, Suzuki T, et al
    Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.
    Biochem Biophys Res Commun. 2019 May 9. pii: S0006-291X(19)30887.
    PubMed     Abstract available


    December 2018
  8. ZHENG Y, Shimamoto S, Maruno T, Kobayashi Y, et al
    N-terminal HCV core protein fragment decreases 20S proteasome activity in the presence of PA28gamma.
    Biochem Biophys Res Commun. 2018 Dec 31. pii: S0006-291X(18)32848.
    PubMed     Abstract available


    April 2018
  9. GANESAN M, Dagur RS, Makarov E, Poluektova LI, et al
    Matrix stiffness regulate apoptotic cell death in HIV-HCV co-infected hepatocytes: Importance for liver fibrosis progression.
    Biochem Biophys Res Commun. 2018 Apr 18. pii: S0006-291X(18)30923.
    PubMed     Abstract available


  10. TERAOKA Y, Uchida T, Imamura M, Osawa M, et al
    Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
    Biochem Biophys Res Commun. 2018 Apr 2. pii: S0006-291X(18)30770.
    PubMed     Abstract available


    January 2018
  11. LI Z, Liu Q
    Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
    Biochem Biophys Res Commun. 2018 Jan 31. pii: S0006-291X(18)30199.
    PubMed     Abstract available


    January 2017
  12. SMIRNOVA OA, Keinanen TA, Ivanova ON, Hyvonen MT, et al
    Hepatitis C virus alters metabolism of biogenic polyamines by affecting expression of key enzymes of their metabolism.
    Biochem Biophys Res Commun. 2017 Jan 9. pii: S0006-291X(17)30041.
    PubMed     Abstract available


    September 2016
  13. ZHANG X, Wang T, Dai X, Zhang Y, et al
    Golgi protein 73 facilitates the interaction of hepatitis C virus NS5A with apolipoprotein E to promote viral particle secretion.
    Biochem Biophys Res Commun. 2016 Sep 30. pii: S0006-291X(16)31626.
    PubMed     Abstract available


  14. CUI W, Li Y, Xu K, Chen G, et al
    miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA.
    Biochem Biophys Res Commun. 2016 Sep 15. pii: S0006-291X(16)31536.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: